Sadayuki Kawai

Shizuoka, 4205827, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.

Journal: Journal of gastrointestinal oncology

Published: September 09, 2022

Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).

Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).

Journal: The Tohoku journal of experimental medicine

Published: May 31, 2021

REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.

REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.

Journal: Future oncology (London, England)

Published: September 21, 2020

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis.

Journal: BMC cancer

Published: September 02, 2020

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.

Journal: BMC cancer

Published: November 01, 2019

Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck.

Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck.

Journal: International journal of clinical oncology

Published: August 28, 2019

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).

Journal: Clinical colorectal cancer

Published: July 19, 2019

Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy.

Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy.

Journal: World journal of gastroenterology

Published: May 08, 2019

Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy.

Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy.

Journal: Japanese journal of clinical oncology

Published: March 15, 2019

Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer.

Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer.

Journal: International journal of clinical oncology

Published: April 24, 2018

Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.

Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.

Journal: International journal of clinical oncology

Published: January 16, 2018

Three Patients with Gastric Cancer Who Underwent Surgery during Ramucirumab Treatment

Three Patients with Gastric Cancer Who Underwent Surgery during Ramucirumab Treatment

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: November 16, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026